Phylo Brings Biomni Lab AI Agents to Bayer

Oct 22, 2026
Phylo will provide Bayer scientists with access to Biomni Lab for drug discovery workflows involving scientific literature, biomedical data and omics evidence.

Phylo is partnering with Bayer to deploy Biomni Lab for drug discovery research, Phylo announced in a press release.

Under the agreement, Bayer scientists will receive full access to the agentic AI platform. They will use it to assemble scientific literature, biomedical data and omics evidence in one workspace.

Biomni Lab records the sources, methods and execution behind its results. Researchers can inspect this information and apply their own scientific judgment when assessing evidence.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.